Literature DB >> 33990401

Is 18F-FDG PET/CT Effective in Identifying True Residual Disease After Treatment of Pediatric PTLD?

Batool El-Atoum1, Mark Ebert, Brian Bucher, Zeinab Afify.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33990401      PMCID： PMC8717193          DOI： 10.2967/jnumed.121.262414

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   11.082


× No keyword cloud information.
  4 in total

1.  18F-FDG PET/CT in the Diagnostic and Treatment Evaluation of Pediatric Posttransplant Lymphoproliferative Disorders.

Authors:  Filipe M Montes de Jesus; Andor W J M Glaudemans; Wim J Tissing; Rudi A J O Dierckx; Stefano Rosati; Arjan Diepstra; Walter Noordzij; Thomas C Kwee
Journal:  J Nucl Med       Date:  2020-01-31       Impact factor: 10.057

2.  Role of interim and end of treatment positron emission tomography for response assessment and prediction of relapse in posttransplant lymphoproliferative disorder.

Authors:  Ciska-Anne Van Keerberghen; Karolien Goffin; Vibeke Vergote; Thomas Tousseyn; Gregor Verhoef; Annouschka Laenen; Peter Vandenberghe; Daan Dierickx; Olivier Gheysens
Journal:  Acta Oncol       Date:  2019-04-29       Impact factor: 4.089

3.  The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma.

Authors:  Deepa Bhojwani; Mary B McCarville; John K Choi; Jennifer Sawyer; Monika L Metzger; Hiroto Inaba; Andrew M Davidoff; Robert Gold; Barry L Shulkin; John T Sandlund
Journal:  Br J Haematol       Date:  2014-11-10       Impact factor: 6.998

4.  Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis.

Authors:  F M Montes de Jesus; T C Kwee; M Nijland; X U Kahle; G Huls; R A J O Dierckx; T van Meerten; O Gheysens; D Dierickx; V Vergote; W Noordzij; A W J M Glaudemans
Journal:  Crit Rev Oncol Hematol       Date:  2018-09-19       Impact factor: 6.312
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.